Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics Inc.
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
61,14 €
-0,36 %
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $72.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $75.00 price target on the stock, up previously from $62.00.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Morgan Stanley from $75.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at HC Wainwright from $75.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at HC Wainwright from $85.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target lowered by analysts at Morgan Stanley from $80.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in BankUnited Inc. diskutieren